Chimerix Inc. (CMRX) 3.71 $CMRX
Chimerix to Participate in Panel on North Carolina's Role in Biodefense Preparation at Medical, Biomedical and Biodefense Symposium
GlobeNewswire - Tue Jun 07, 7:00AM CDT
Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals in areas of high unmet medical need, today announced that M. Michelle Berrey, M.D., M.P.H., President and Chief Executive Officer of Chimerix, will participate in a panel focused on North Carolina's role in biodefense preparation at the "Medical, Biomedical and Biodefense: Support to the Warfighter Symposium" being held June 7-8, 2016 in Research Triangle Park, North Carolina.
CMRX: 3.71 (-0.08)
Premarket Research Report Covering the Biotech Industry
ACCESSWIRE - Mon Jun 06, 8:15AM CDT
LONDON, UK / ACCESSWIRE / June 6, 2016 / ActiveWallSt.com announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the biotech industry. Companies recently under review include Incyte, Chimerix, Lexicon Pharma, and Synthetic Biologics. Register with us now for your free membership and see our complete reports on these equities at:
SYN: 1.74 (-0.02), CMRX: 3.71 (-0.08), LXRX: 13.65 (-0.28), INCY: 80.02 (-1.64)
Bellicum Appoints Jim Daly to its Board of Directors
BusinessWire - Wed May 18, 6:00AM CDT
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the appointment of Jim Daly to its Board of Directors. Mr. Daly has over 30 years of experience leading U.S. and global businesses in the biopharmaceutical industry and currently serves as a Director of ACADIA Pharmaceuticals, Halozyme Therapeutics, and Chimerix, Inc.
ACAD: 32.29 (-1.21), BLCM: 12.58 (-0.41), CMRX: 3.71 (-0.08)
Chimerix Announces Top-Line Interim AdVise Data and First Quarter 2016 Financial Results
GlobeNewswire - Mon May 09, 6:30AM CDT
- Maintains strong financial position with $314.5 million in capital at quarter end -
CMRX: 3.71 (-0.08)
Chimerix to Announce First Quarter 2016 Financial Results on May 9, 2016
GlobeNewswire - Tue May 03, 5:00PM CDT
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that it will host a live conference call and audio webcast on Monday, May 9, 2016 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2016, and to provide a business overview.
CMRX: 3.71 (-0.08)
Why Investors Are So Bullish on This Small Biotech
ACCESSWIRE - Wed Mar 30, 9:30AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 30, 2016 / One major shift we are looking for in healthcare in the coming months is an increased emphasis on bio-electronic medicine, as opposed to pure drug plays. The reason is that the devices currently under development hold the potential to be more effective, with fewer side effects than traditional drug treatments.
ESPR: 16.98 (+0.08), CMRX: 3.71 (-0.08), GERN: 2.65 (-0.10), CYTX: 1.96 (-0.04), CLDX: 4.45 (-0.12), SGMO: 5.63 (-0.29), PTCT: 6.53 (-0.47), ATHX: 1.90 (-0.10), MNKD: 1.19 (-0.05)
Are These Biotech Stocks Worth your Attention? CELG, ARIA, EXEL, and CMRX
ACCESSWIRE - Tue Mar 22, 8:02AM CDT
NEW YORK, NY / ACCESSWIRE / March 22, 2016 / Despite the challenges that continue to press the Biotech industry, ValuableInvestment.com, this morning, turns its focus on the following Healthcare companies: Celgene Corp. (NASDAQ: CELG), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Exelixis Inc. (NASDAQ: EXEL), and Chimerix Inc. (NASDAQ: CMRX). Find out why these stocks are under our microscope by clicking the link below:
CMRX: 3.71 (-0.08), ARIA: 7.41 (-0.13), EXEL: 7.80 (-0.05), CELG: 98.07 (-2.59), CELGZ: 1.36 (-0.09)
Biotechs in the News
ACCESSWIRE - Mon Mar 21, 8:00AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 21, 2016 / The past few weeks have been exciting for biotechnology stocks and this week see no difference. Several biotechs have disclosed news this week that has the market reacting favorably. Here are a few stocks you should take an immediate look at:
CPXX: 30.18 (+0.03), INO: 9.38 (-0.47), CMRX: 3.71 (-0.08), ORPN: 1.65 (-0.09), BLRX: 0.80 (-0.02)
Chimerix to Present at the Barclays Global Healthcare Conference
GlobeNewswire - Wed Mar 09, 7:30AM CST
Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals to address unmet medical needs, today announced that Linda M. Richardson, Chief Commercial Officer of Chimerix, will present at the Barclays Global Healthcare Conference on Wednesday, March 16, 2016 at 2:35 p.m. ET at the Loews Miami Beach Hotel in Miami, FL.
CMRX: 3.71 (-0.08)
A Potential Answer To Antibiotic Resistance
ACCESSWIRE - Mon Mar 07, 12:22PM CST
NEW YORK, NY / ACCESSWIRE / March 7, 2016 / In a report modeled by Rand Europe and KPMG, and presented to the UK government at the end of 2014, analysts expect that by 2050, superbugs will kill more patients globally than cancer. Not something that is currently in the public consciousness, but a terrifying statistic nonetheless.
JNJ: 116.35 (-1.03), CMRX: 3.71 (-0.08), MRK: 56.47 (-1.21), CDTX: 10.49 (-0.41), GSK: 41.41 (-1.15)
Chimerix Announces Presentation of Detailed Results From Phase 3 SUPPRESS Trial at BMT Tandem Meetings
GlobeNewswire - Sat Feb 20, 8:15PM CST
Brincidofovir Shows On-Treatment Antiviral Effect in HCT Setting Despite Trial Not Meeting Primary Endpoint
CMRX: 3.70 (-0.09)
Chimerix Presents Positive Results From Brincidofovir Pivotal Study in Animal Model for Smallpox
GlobeNewswire - Mon Feb 08, 1:03PM CST
Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today presented positive results from a pivotal study of its antiviral, brincidofovir, in an animal model for smallpox at the ASM Biodefense and Emerging Diseases Research Meeting in Arlington, Virginia.
CMRX: 3.70 (-0.09)
Latest Global Chimerix, Inc. Market Research Report Product Pipeline Review 2015 - Acute Market Reports
M2 - Fri Feb 05, 5:12AM CST
'CHIMERIX, INC. - Product Pipeline Review - 2015', provides an overview of the CHIMERIX, INC.'s pharmaceutical research and development focus.
CMRX: 3.70 (-0.09)
WHO Declares Zika A Health Emergency of International Concern: 5 Companies Developing Technologies in the Fight against the Epidemic
ACCESSWIRE - Wed Feb 03, 8:22AM CST
WINDSOR, ON / ACCESSWIRE / February 3, 2016 / The Wealthy Biotech Trader (or "WBT"
, an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known, biotech, pharma and medical device stocks making news and subsequent market moves, has researched several stocks on the front lines in the fight against Zika, an epidemic spreading from South America that causes flu-like symptoms but is feared to cause horrible birth defects in babies whose mothers become infected.
INO: 9.38 (-0.47), BCRX: 2.79 (-0.15), CMRX: 3.70 (-0.09), XON: 25.37 (+0.17)
Chimerix Inc. Is Roaring Higher Again -- Here's Why
Brian Feroldi, The Motley Fool - Motley Fool - Wed Jan 20, 2:54PM CST
What: Investors in Chimerix managed to buck the market wide sell-off today as shares of the clinical-stage biopharma jumped more than 13% as of 2:50 p.m. ET after an analyst published a bullish forecast for the company's stock. So what: ...
CMRX: 3.70 (-0.09), XBI: 53.09 (-1.43)
Strength Seen in Chimerix (CMRX): Stock Rises 8.1%
Zacks Equity Research - Zacks Investment Research - Wed Jan 20, 7:00AM CST
Chimerix (CMRX) was a big mover last session, with its shares rising just over 8% on the day.
CMRX: 3.70 (-0.09), ABAX: 46.22 (-0.89)
Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/d53rgr/cytomegalovirus) has announced the addition of the "Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cytomegalovirus HHV-5 Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cytomegalovirus HHV-5 Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Cytomegalovirus HHV-5 Infections Overview - Therapeutics Development - Pipeline Products for Cytomegalovirus HHV-5 Infections - Overview - Pipeline Products for Cytomegalovirus HHV-5 Infections - Comparative Analysis - Cytomegalovirus HHV-5 Infections - Therapeutics under Development by Companies - Cytomegalovirus HHV-5 Infections - Therapeutics under Investigation by Universities/Institutes - Cytomegalovirus HHV-5 Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Cytomegalovirus HHV-5 Infections - Products under Development by Companies - Cytomegalovirus HHV-5 Infections - Products under Investigation by Universities/Institutes - Cytomegalovirus HHV-5 Infections - Companies Involved in Therapeutics Development - AIMM Therapeutics B.V. - Altor BioScience Corporation - Applied Immune Technologies Ltd - Astellas Pharma Inc. - Atara Biotherapeutics, Inc. - Bionor Pharma ASA - Biotest AG - CAP-CMV GmbH - Cell Medica Limited - Chimerix, Inc. - China Biologic Products, Inc. - CyTuVax B.V. - GlaxoSmithKline Plc - Hookipa Biotech AG - Humabs BioMed SA - iQur Limited - Kadmon Corporation, LLC - Lead Discovery Center GmbH - Merck & Co., Inc. - Microbiotix, Inc. - Novartis AG - Pfizer Inc. - Phoenix Biotechnology, Inc. - Savoy Pharmaceuticals, Inc. - Trellis Bioscience, Inc. - Vakzine Projekt Management GmbH - VBI Vaccines Inc. - Vical Incorporated For more information visit http://www.researchandmarkets.com/research/d5...egalovirus
CBPO: 102.47 (-3.67), VICL: 4.40 (-0.20), CMRX: 3.70 (-0.09), PFE: 34.11 (-0.48), MRK: 56.47 (-1.21), ATRA: 21.56 (-0.50), VBIV: 3.89 (-0.04), GSK: 41.41 (-1.15), NVS: 78.84 (-1.83)
4 Small Cap NASDAQ/NYSE Stocks That Are Trading with Heavy Volume Today
ACCESSWIRE - Tue Jan 19, 11:52AM CST
NEW YORK, NY / ACCESSWIRE / January 19, 2016 / The Stock Expert is issuing a report on four stocks to watch. CMRX, AEZS, TMST and GBSN have been attracting the attention of major investors today. Continue reading to find out why.
GBSN: 1.88 (+0.14), TMST: 9.20 (-0.74), CMRX: 3.70 (-0.09), AEZS: 3.36 (-0.12)
Why Chimerix Inc. Is Up Big Today
Brian Feroldi, The Motley Fool - Motley Fool - Tue Jan 19, 11:50AM CST
What: Shares of Chimerix , a clinical-stage biopharma focused on antiviral drugs, rose more than 13% as of 11:15 a.m. ET. So what: There doesn't appear to be any news today to justify the strong share price move, so it's likely that shares...
ESPR: 16.98 (+0.08), CMRX: 3.70 (-0.09)
Chimerix to Participate in Panel on North Carolina's Role in Biodefense Preparation at Medical, Biomedical and Biodefense Symposium
GlobeNewswire - Tue Jun 07, 7:00AM CDT
Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals in areas of high unmet medical need, today announced that M. Michelle Berrey, M.D., M.P.H., President and Chief Executive Officer of Chimerix, will participate in a panel focused on North Carolina's role in biodefense preparation at the "Medical, Biomedical and Biodefense: Support to the Warfighter Symposium" being held June 7-8, 2016 in Research Triangle Park, North Carolina.
CMRX: 3.71 (-0.08)
Premarket Research Report Covering the Biotech Industry
ACCESSWIRE - Mon Jun 06, 8:15AM CDT
LONDON, UK / ACCESSWIRE / June 6, 2016 / ActiveWallSt.com announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the biotech industry. Companies recently under review include Incyte, Chimerix, Lexicon Pharma, and Synthetic Biologics. Register with us now for your free membership and see our complete reports on these equities at:
SYN: 1.74 (-0.02), CMRX: 3.71 (-0.08), LXRX: 13.65 (-0.28), INCY: 80.02 (-1.64)
Bellicum Appoints Jim Daly to its Board of Directors
BusinessWire - Wed May 18, 6:00AM CDT
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the appointment of Jim Daly to its Board of Directors. Mr. Daly has over 30 years of experience leading U.S. and global businesses in the biopharmaceutical industry and currently serves as a Director of ACADIA Pharmaceuticals, Halozyme Therapeutics, and Chimerix, Inc.
ACAD: 32.29 (-1.21), BLCM: 12.58 (-0.41), CMRX: 3.71 (-0.08)
Chimerix Announces Top-Line Interim AdVise Data and First Quarter 2016 Financial Results
GlobeNewswire - Mon May 09, 6:30AM CDT
- Maintains strong financial position with $314.5 million in capital at quarter end -
CMRX: 3.71 (-0.08)
Chimerix to Announce First Quarter 2016 Financial Results on May 9, 2016
GlobeNewswire - Tue May 03, 5:00PM CDT
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that it will host a live conference call and audio webcast on Monday, May 9, 2016 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2016, and to provide a business overview.
CMRX: 3.71 (-0.08)
Why Investors Are So Bullish on This Small Biotech
ACCESSWIRE - Wed Mar 30, 9:30AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 30, 2016 / One major shift we are looking for in healthcare in the coming months is an increased emphasis on bio-electronic medicine, as opposed to pure drug plays. The reason is that the devices currently under development hold the potential to be more effective, with fewer side effects than traditional drug treatments.
ESPR: 16.98 (+0.08), CMRX: 3.71 (-0.08), GERN: 2.65 (-0.10), CYTX: 1.96 (-0.04), CLDX: 4.45 (-0.12), SGMO: 5.63 (-0.29), PTCT: 6.53 (-0.47), ATHX: 1.90 (-0.10), MNKD: 1.19 (-0.05)
Are These Biotech Stocks Worth your Attention? CELG, ARIA, EXEL, and CMRX
ACCESSWIRE - Tue Mar 22, 8:02AM CDT
NEW YORK, NY / ACCESSWIRE / March 22, 2016 / Despite the challenges that continue to press the Biotech industry, ValuableInvestment.com, this morning, turns its focus on the following Healthcare companies: Celgene Corp. (NASDAQ: CELG), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Exelixis Inc. (NASDAQ: EXEL), and Chimerix Inc. (NASDAQ: CMRX). Find out why these stocks are under our microscope by clicking the link below:
CMRX: 3.71 (-0.08), ARIA: 7.41 (-0.13), EXEL: 7.80 (-0.05), CELG: 98.07 (-2.59), CELGZ: 1.36 (-0.09)
Biotechs in the News
ACCESSWIRE - Mon Mar 21, 8:00AM CDT
LAS VEGAS, NV / ACCESSWIRE / March 21, 2016 / The past few weeks have been exciting for biotechnology stocks and this week see no difference. Several biotechs have disclosed news this week that has the market reacting favorably. Here are a few stocks you should take an immediate look at:
CPXX: 30.18 (+0.03), INO: 9.38 (-0.47), CMRX: 3.71 (-0.08), ORPN: 1.65 (-0.09), BLRX: 0.80 (-0.02)
Chimerix to Present at the Barclays Global Healthcare Conference
GlobeNewswire - Wed Mar 09, 7:30AM CST
Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals to address unmet medical needs, today announced that Linda M. Richardson, Chief Commercial Officer of Chimerix, will present at the Barclays Global Healthcare Conference on Wednesday, March 16, 2016 at 2:35 p.m. ET at the Loews Miami Beach Hotel in Miami, FL.
CMRX: 3.71 (-0.08)
A Potential Answer To Antibiotic Resistance
ACCESSWIRE - Mon Mar 07, 12:22PM CST
NEW YORK, NY / ACCESSWIRE / March 7, 2016 / In a report modeled by Rand Europe and KPMG, and presented to the UK government at the end of 2014, analysts expect that by 2050, superbugs will kill more patients globally than cancer. Not something that is currently in the public consciousness, but a terrifying statistic nonetheless.
JNJ: 116.35 (-1.03), CMRX: 3.71 (-0.08), MRK: 56.47 (-1.21), CDTX: 10.49 (-0.41), GSK: 41.41 (-1.15)
Chimerix Announces Presentation of Detailed Results From Phase 3 SUPPRESS Trial at BMT Tandem Meetings
GlobeNewswire - Sat Feb 20, 8:15PM CST
Brincidofovir Shows On-Treatment Antiviral Effect in HCT Setting Despite Trial Not Meeting Primary Endpoint
CMRX: 3.70 (-0.09)
Chimerix Presents Positive Results From Brincidofovir Pivotal Study in Animal Model for Smallpox
GlobeNewswire - Mon Feb 08, 1:03PM CST
Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today presented positive results from a pivotal study of its antiviral, brincidofovir, in an animal model for smallpox at the ASM Biodefense and Emerging Diseases Research Meeting in Arlington, Virginia.
CMRX: 3.70 (-0.09)
Latest Global Chimerix, Inc. Market Research Report Product Pipeline Review 2015 - Acute Market Reports
M2 - Fri Feb 05, 5:12AM CST
'CHIMERIX, INC. - Product Pipeline Review - 2015', provides an overview of the CHIMERIX, INC.'s pharmaceutical research and development focus.
CMRX: 3.70 (-0.09)
WHO Declares Zika A Health Emergency of International Concern: 5 Companies Developing Technologies in the Fight against the Epidemic
ACCESSWIRE - Wed Feb 03, 8:22AM CST
WINDSOR, ON / ACCESSWIRE / February 3, 2016 / The Wealthy Biotech Trader (or "WBT"
, an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known, biotech, pharma and medical device stocks making news and subsequent market moves, has researched several stocks on the front lines in the fight against Zika, an epidemic spreading from South America that causes flu-like symptoms but is feared to cause horrible birth defects in babies whose mothers become infected. INO: 9.38 (-0.47), BCRX: 2.79 (-0.15), CMRX: 3.70 (-0.09), XON: 25.37 (+0.17)
Chimerix Inc. Is Roaring Higher Again -- Here's Why
Brian Feroldi, The Motley Fool - Motley Fool - Wed Jan 20, 2:54PM CST
What: Investors in Chimerix managed to buck the market wide sell-off today as shares of the clinical-stage biopharma jumped more than 13% as of 2:50 p.m. ET after an analyst published a bullish forecast for the company's stock. So what: ...
CMRX: 3.70 (-0.09), XBI: 53.09 (-1.43)
Strength Seen in Chimerix (CMRX): Stock Rises 8.1%
Zacks Equity Research - Zacks Investment Research - Wed Jan 20, 7:00AM CST
Chimerix (CMRX) was a big mover last session, with its shares rising just over 8% on the day.
CMRX: 3.70 (-0.09), ABAX: 46.22 (-0.89)
Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/d53rgr/cytomegalovirus) has announced the addition of the "Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cytomegalovirus HHV-5 Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cytomegalovirus HHV-5 Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Cytomegalovirus HHV-5 Infections Overview - Therapeutics Development - Pipeline Products for Cytomegalovirus HHV-5 Infections - Overview - Pipeline Products for Cytomegalovirus HHV-5 Infections - Comparative Analysis - Cytomegalovirus HHV-5 Infections - Therapeutics under Development by Companies - Cytomegalovirus HHV-5 Infections - Therapeutics under Investigation by Universities/Institutes - Cytomegalovirus HHV-5 Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Cytomegalovirus HHV-5 Infections - Products under Development by Companies - Cytomegalovirus HHV-5 Infections - Products under Investigation by Universities/Institutes - Cytomegalovirus HHV-5 Infections - Companies Involved in Therapeutics Development - AIMM Therapeutics B.V. - Altor BioScience Corporation - Applied Immune Technologies Ltd - Astellas Pharma Inc. - Atara Biotherapeutics, Inc. - Bionor Pharma ASA - Biotest AG - CAP-CMV GmbH - Cell Medica Limited - Chimerix, Inc. - China Biologic Products, Inc. - CyTuVax B.V. - GlaxoSmithKline Plc - Hookipa Biotech AG - Humabs BioMed SA - iQur Limited - Kadmon Corporation, LLC - Lead Discovery Center GmbH - Merck & Co., Inc. - Microbiotix, Inc. - Novartis AG - Pfizer Inc. - Phoenix Biotechnology, Inc. - Savoy Pharmaceuticals, Inc. - Trellis Bioscience, Inc. - Vakzine Projekt Management GmbH - VBI Vaccines Inc. - Vical Incorporated For more information visit http://www.researchandmarkets.com/research/d5...egalovirus
CBPO: 102.47 (-3.67), VICL: 4.40 (-0.20), CMRX: 3.70 (-0.09), PFE: 34.11 (-0.48), MRK: 56.47 (-1.21), ATRA: 21.56 (-0.50), VBIV: 3.89 (-0.04), GSK: 41.41 (-1.15), NVS: 78.84 (-1.83)
4 Small Cap NASDAQ/NYSE Stocks That Are Trading with Heavy Volume Today
ACCESSWIRE - Tue Jan 19, 11:52AM CST
NEW YORK, NY / ACCESSWIRE / January 19, 2016 / The Stock Expert is issuing a report on four stocks to watch. CMRX, AEZS, TMST and GBSN have been attracting the attention of major investors today. Continue reading to find out why.
GBSN: 1.88 (+0.14), TMST: 9.20 (-0.74), CMRX: 3.70 (-0.09), AEZS: 3.36 (-0.12)
Why Chimerix Inc. Is Up Big Today
Brian Feroldi, The Motley Fool - Motley Fool - Tue Jan 19, 11:50AM CST
What: Shares of Chimerix , a clinical-stage biopharma focused on antiviral drugs, rose more than 13% as of 11:15 a.m. ET. So what: There doesn't appear to be any news today to justify the strong share price move, so it's likely that shares...
ESPR: 16.98 (+0.08), CMRX: 3.70 (-0.09)
